http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Saki Kotaka,Eiji Kondo,Yosuke Kawai,Kota Okamoto,Yasuyuki Kishigami,Takaharu Yamawaki,Kenji Nagao,Toru Hirata,Shiro Suzuki 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.5
Objective: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribution of the platinum-free interval to the efficacy of subsequent chemotherapy for advanced cervical cancer. Methods: We retrospectively identified 115 patients with metastatic, recurrent, or persistent cervical cancer treated with platinum-paclitaxel chemotherapy plus bevacizumab at 7 institutions between 2015 and 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in patients who received bevacizumab maintenance therapy and those who did not. We also analyzed the adverse events associated with bevacizumab and survival time from the start of subsequent chemotherapy in both groups. Results: Following platinum-paclitaxel plus bevacizumab chemotherapy, 34 patients received bevacizumab maintenance therapy and 81 patients did not. Of the 115 patients, 56 received chemotherapy for subsequent relapse. Although bevacizumab maintenance therapy prolonged PFS (median of 16.0 months vs. 9.0 months, p=0.041), significant differences were not observed in OS (p=0.374). Furthermore, bevacizumab maintenance therapy did not prolong OS and PFS after the start of subsequent chemotherapy (p=0.663 and p=0.136, respectively). Bevacizumab maintenance therapy significantly increased hypertension (p=0.035) and proteinuria (p=0.005) but did not cause complications leading to death. Conclusion: Bevacizumab single-maintenance therapy for advanced cervical cancer can be considered in selected cases, such as those with acceptable bevacizumab-related side effects. The outcomes of our study will likely contribute to decision-making regarding practical treatment strategies.
Surgical outcomes of pancreatectomy with jejunal vein resection for pancreatic head cancer
Yuichi NAGAKAWA,Jin-Young JANG,Manabu KAWAI,Song Cheol KIM,Yosuke INOUE,Yasuhiro YABUSHITA,Jin Seok HEO,Masayuki HONDA,Teiichi SUGIURA,Shingo KAGAWA,Aoi HAYASAKI,Wooil KWON,Kenichiro UEMURA,Ho-Seong H 한국간담췌외과학회 2022 Annals of hepato-biliary-pancreatic surgery Vol.26 No.-